Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among: 1 Perianal ...

ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...

The data include new Phase 3 AFFIRM findings for SKYRIZI (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, as well as open-label extension analyses demonstrating long-term ...

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...

Around it, AbbVie ABBV+1.49% also presented analyses of Skyrizi's open-label extension showing sustained endoscopic outcomes ...

Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a Phase 3b extension study to track the long term ...

The Crohn's & Colitis Foundation will host its 59th Annual Gala at the Edison Ballroom, featuring Broadway performances and celebrating 25 years of ...

UCLA Health awarded a $4 million grant to study why some ulcerative colitis patients continue to experience irritable bowel ...

This article selects and organizes clinical trials from ClinicalTrials.gov (CTgov) that were 'newly registered' or had a ...

Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory ...

Yusimry is indicated to treat a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn’s ...

Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...